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Introduction {#sec001}
============

Members of the genus *Enterobacter*, belonging to the *Enterobacteriaceae*, are Gram-negative bacilli that inhabit terrestrial and aquatic environments including water, sewage, and soil, as well as the intestinal tracts of mammals \[[@pone.0174178.ref001]\]. *Enterobacter cloacae* is the most medically-important species in the genus and is responsible for nosocomial infections in humans \[[@pone.0174178.ref002]\]. In companion animals, this bacterial species is rarely associated with urinary tract infections, wound infections, pneumonia, intravenous catheter site infections, otitis externa, peritonitis, and dermatitis \[[@pone.0174178.ref003]\].

The emergence of antimicrobial resistance among *Enterobacter* spp. is of great concern worldwide in human medicine \[[@pone.0174178.ref001],[@pone.0174178.ref002]\]. It increases the risk of antimicrobial treatment failure not only in humans but also in companion animals. Similarly, the emergence of antimicrobial-resistant bacteria in companion animals may have important human public health consequences if isolates are transmitted to humans from their pets \[[@pone.0174178.ref004],[@pone.0174178.ref005]\]. Understanding the prevalence of antimicrobial resistance among *Enterobacter* spp. isolates is thus important both from veterinary medicine and public health perspectives.

Resistance to extended-spectrum cephalosporins (ESC) among Gram-negative bacteria, including *Enterobacter* spp., is of particular concern \[[@pone.0174178.ref006]\]. In *Enterobacter* spp., ESC resistance is most typically caused by the overproduction of AmpC β-lactamases, which is due to the derepression of a chromosomal gene or the acquisition of a transferable AmpC β-lactamase \[[@pone.0174178.ref001],[@pone.0174178.ref006]\]. In addition, extended-spectrum β-lactamases (ESBLs) and carbapenemases have been identified in *Enterobacter* spp. \[[@pone.0174178.ref007]\], exacerbating the issue of ESC resistance. An even greater concern is that most ESC-resistant *Enterobacteriaceae* exhibit multidrug resistance, including fluoroquinolone resistance, mainly due to chromosomal mutations in the enzymes targeted by the drug, and plasmid-mediated quinolone resistance (PMQR) \[[@pone.0174178.ref008]\]. In recent years, these resistance mechanisms have been well documented among *Enterobacter* spp. isolates from companion animals across several countries, including Australia \[[@pone.0174178.ref009],[@pone.0174178.ref010]\], France \[[@pone.0174178.ref011]\], and Germany \[[@pone.0174178.ref012]\]. However, the status of emerging antimicrobial resistance among *Enterobacter* spp. in companion animals remains unknown in many other countries, including Japan.

The aim of the present study was to investigate the prevalence of antimicrobial resistance, and provide molecular characterization of ESC resistance and PMQR among *Enterobacter* spp. isolates from clinical specimens taken from dogs and cats that visited veterinary hospitals throughout Japan. A further aim was to assess the epidemiological relatedness of ESC-resistant *Enterobacter* spp. strains.

Materials and methods {#sec002}
=====================

Bacterial isolates {#sec003}
------------------

A total of 60 clinical isolates of *Enterobacter* spp., consisting of *E*. *cloacae* (n = 44), *E*. *aerogenes* (n = 10), and *E*. *asburiae* (n = 6), were collected from dogs (n = 44) and cats (n = 16) kept by different owners that visited veterinary hospitals between 2003 and 2015. These hospitals were located at the following 15 prefectures in Japan: Hokkaido, Fukui, Gunma, Ibaraki, Saitama, Tokyo, Chiba, Kanagawa, Nagano, Aichi, Osaka, Hyogo, Tottori, Yamaguchi, and Fukuoka prefectures. The specimens were isolated from various anatomical sites, assessed as being sites of bacterial infection by clinical veterinarians, including the urinary tract (n = 27), pus from unspecified locations (n = 10), nasal cavity (n = 5), ear (n = 4), skin (n = 2), eye (n = 2), ascites (n = 2), and the other sites (n = 8). The details of *Enterobacter* spp. isolates used in this study are shown in [S1 Table](#pone.0174178.s001){ref-type="supplementary-material"}. No information was available regarding previous antimicrobial treatment of the dogs and cats. Ethical approval was not needed according to the ethical guidelines for epidemiological research by the Japanese government because this study focused on bacterial aspects. Bacterial identification was conducted by assessing the growth status on CHROMagar orientation medium \[[@pone.0174178.ref013]\], using the API 20E kit (SYSMEX bioMérieux Co., Ltd., Tokyo, Japan), and MALDI-TOF MS with the Bruker MALDI Biotyper system (Bruker Daltonics, Bremen, Germany) \[[@pone.0174178.ref014]\]. All confirmed *Enterobacter* spp. isolates were stored at −80°C in 10% skim milk.

Antimicrobial susceptibility testing {#sec004}
------------------------------------

Susceptibilities to ampicillin (AMP, Wako Pure Chemical Industries, Ltd., Osaka, Japan), amoxicillin-clavulanic acid (ACV, Sigma-Aldrich Co. LLC., Tokyo, Japan), cefmetazole (CMZ, Sigma-Aldrich), cefotaxime (CTX, Wako Pure Chemical), ceftazidime (CAZ, Sigma-Aldrich), meropenem (MPM, Wako Pure Chemical), tetracycline (TET, Wako Pure Chemical), gentamicin (GEN, Sigma-Aldrich), chloramphenicol (CHL, Wako Pure Chemical), trimethoprim/sulfamethoxazole (TMS, Wako Pure Chemical), and ciprofloxacin (CIP, Wako Pure Chemical) were determined. Susceptibility testing was conducted using the agar dilution method, according to the Clinical and Laboratory Standards Institute (CLSI) guidelines \[[@pone.0174178.ref015]\]. The results obtained were interpreted according to the criteria contained within the CLSI guidelines \[[@pone.0174178.ref016],[@pone.0174178.ref017]\]. *Escherichia coli* ATCC 25922 was used as a control strain.

Phenotypic analysis of ESC-resistant *Enterobacter* spp. strains {#sec005}
----------------------------------------------------------------

ESC-resistant \[i.e. minimum inhibitory concentration (MIC) for CTX or CAZ of ≥ 2 or 8 μg/mL, respectively\] strains were screened for ESBLs by the double-disc synergy test using CTX, CAZ, cefepime, and ACV disks on Mueller-Hinton agar plates without or with 200 μg/mL cloxacillin \[[@pone.0174178.ref018]\]. In addition, ESC-resistant isolates without synergism with clavulanate and with inhibition zones augmented upon cloxacillin were classified as organisms overexpressing AmpC β-lactamase \[[@pone.0174178.ref019]\].

Isolates with an MIC for MPM of ≥ 0.25 μg/mL, the recommended cut-off value for carbapenemase-producing *Enterobacteriaceae* by the European Committee on Antimicrobial Susceptibility Testing \[[@pone.0174178.ref020]\], were screened for the production of *Klebsiella pneumoniae* carbapenemase (KPC) and metallo-β-lactamase, and porin loss, using a D70C carbapenemase detection set (MASTDISCS^™^ID, UK).

Characterization of β-lactamase genes and PMQR in ESC-resistant *Enterobacter* spp. isolates {#sec006}
--------------------------------------------------------------------------------------------

Genomic DNA from each of the isolates was prepared by suspending several colonies in 0.5 mL of water and boiling for 10 min. These samples were used as templates for further genetic analyses. All of the ESC-resistant strains were screened for class A β-lactamase genes (i.e. *bla*TEM and *bla*SHV), which were identified using PCR and DNA sequencing, as previously reported \[[@pone.0174178.ref021]\]. Class D β-lactamase genes (*bla*OXA) were detected using multiplex PCR \[[@pone.0174178.ref022]\], and were amplified and bi-directionally sequenced using specific primers \[[@pone.0174178.ref023]\]. In addition, AmpC β-lactamase genes (i.e. the ACC, FOX, MOX, DHA, CIT, and EBC groups) were screened by multiplex PCR \[[@pone.0174178.ref024]\], and were amplified and then bi-directionally sequenced using specific primers \[[@pone.0174178.ref025],[@pone.0174178.ref026]\]. In ESBL-positive strains, the CTX-M-type β-lactamase genes were detected using multiplex PCR \[[@pone.0174178.ref027]\]; for the positive isolates, the genes were amplified and sequenced to identify CTX-M subtypes using group-specific PCR primers \[[@pone.0174178.ref021]\].

All ESC-resistant isolates were screened for eight PMQR genes (i.e. *qnrA*, *qnrB*, *qnrC*, *qnrD*, *qnrS*, *qepA*, *aac(6')-Ib-cr*, and *oqxAB*) using multiplex PCR \[[@pone.0174178.ref028]\]. Positive results were confirmed by individual gene PCRs. Randomly selected PCR products of PMQR genes were directionally sequenced with the same primers for confirmation.

Multilocus sequence typing and pulsed-field gel electrophoresis of ESC-resistant *E*. *cloacae* strains {#sec007}
-------------------------------------------------------------------------------------------------------

For ESC-resistant *E*. *cloacae* strains, multilocus sequence typing (MLST) with seven genes (i.e. *dnaA*, *fusA*, *gyrB*, *leuS*, *pyrG*, *rplB*, and *rpoB*) was carried out as described previously \[[@pone.0174178.ref029]\]. A new sequence type (ST) was submitted to the MLST website and new ST numbers were assigned. The eBURST v3 analysis (<http://eburst.mlst.net/v3/instructions/>) was performed to assess the relatedness between STs.

Pulsed-field gel electrophoresis (PFGE) was performed on ESC-resistant *E*. *cloacae* strains, as previously described \[[@pone.0174178.ref030]\]. DNA embedded in agarose was digested with *Xba*I (Takara Bio, Inc., Tokyo, Japan) and then electrophoresed using CHEF DRIII (Bio-Rad, Hercules, CA, USA). PFGE profiles were digitized for analysis using BioNumerics software (version 5.10; Applied Maths, TX, USA). All fragment sizes within the gel were normalized using the molecular weight method. A similarity matrix was calculated using the Dice coefficient, and cluster analysis was performed using the UPGMA algorithm. A cluster was defined based on a similarity cut-off of 80% with 1.0% optimization and 1.0% band tolerance.

Results {#sec008}
=======

Rates of antimicrobial resistance among *Enterobacter* spp. isolates {#sec009}
--------------------------------------------------------------------

The numbers of isolates with resistance to AMP, ACV, CMZ, CHL, CIP, TET, CAZ, CTX, TMS, GEN, and MPM were 56 (93.3%), 56 (93.3%), 56 (93.3%), 28 (46.7%), 26 (43.3%), 24 (40.0%), 20 (33.3%), 20 (33.3%), 17 (28.3%), 14 (23.3%), and 0 (0%), respectively, in 60 *Enterobacter* spp. clinical isolates ([Fig 1](#pone.0174178.g001){ref-type="fig"}).

![Rates of resistance to 11 antimicrobials among *Enterobacter* isolates (n = 60) from companion animals.\
^a^AMP, ampicillin; ACV, amoxicillin-clavulanic acid; CMZ, cefmetazole; CTX, cefotaxime; CAZ, ceftazidime, MPM, meropenem; TET, tetracycline; GEN, gentamicin; CHL, chloramphenicol; TMS, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin.](pone.0174178.g001){#pone.0174178.g001}

Identification of β-lactamases and PMQR genes in ESC-resistant *Enterobacter* spp. strains {#sec010}
------------------------------------------------------------------------------------------

Resistance to ESC (CTX and CAZ) was detected in 20 isolates, consisting of *E*. *cloacae* (n = 18) and *E*. *asburiae* (n = 2). The double-disc synergy test revealed that 16 of 18 ESC-resistant *E*. *cloacae* strains produced ESBLs, but no *E*. *asburiae* strains displayed this phenotype. Four non-ESBL-producing ESC-resistant strains were phenotypically identified as AmpC hyperproducers. In total, 16 of 60 (26.7%) *Enterobacter* spp. isolates were positive for ESBLs.

[Table 1](#pone.0174178.t001){ref-type="table"} shows the detailed characteristics of 20 ESC-resistant *Enterobacter* spp. strains. The CTX-M-15 (n = 8), SHV-12 (n = 7), and CTX-M-3 (n = 1) were detected in ESBL-producing *E*. *cloacae* strains. As for AmpC β-lactamases, CMY-2 and DHA-1 were detected together with/without ESBLs in two ESC-resistant *E*. *cloacae* strains each, whereas ACT-type genes were detected in two ESC-resistant *E*. *asburiae* strains. TEM-1 and OXA-1 were also detected in 13 and 7 ESC-resistant *E*. *cloacae* strains, respectively. Seven of the ESC-resistant strains had higher MPM MICs (0.25--4 μg/mL) than the screening cut-offs for carbapenemase-positive *Enterobacteriaceae* \[[@pone.0174178.ref018]\]. The results of the disk test indicated that all of the seven strains have porin loss, in addition to ESBLs, but not have carbapenemases. Of the eight PMQR genes tested, *qnrB*, *aac(6')-Ib-cr*, and *qnrS* were detected in 15, 8, and 2 ESC-resistant isolates, respectively.

10.1371/journal.pone.0174178.t001

###### Characterization of 20 ESC-resistant *Enterobacter* spp. strains from dogs and cats in Japan.

![](pone.0174178.t001){#pone.0174178.t001g}

  Strain                    Host   ST                                          AmpC overexpression   ESBL/AmpC         Other β-lactamase   PMQR                      MIC(μg/mL)[^b^](#t001fn002){ref-type="table-fn"}                                                                     
  ------------------------- ------ ------------------------------------------- --------------------- ----------------- ------------------- ------------------------- -------------------------------------------------- ------- ------- ----- ------- ------- ------- ----- ------------- ------
  *E*. *cloacae* (n = 18)                                                                                                                                                                                                                                                                 
  EN13                      Dog    113                                         \+                    Not detected      TEM-1               *qnrS*                    64/32                                              256     64      32    0.125   256     \>256   0.5   \>64/1216     16
  EN41                      Dog    114                                         \-                    CTX-M-15          OXA-1               *aac(6')-Ib-cr*, *qnrB*   64/32                                              \>256   256     32    0.06    8       32      32    \>64/1216     128
  EN33                      Dog    121                                         \-                    CTX-M-15          TEM-1, OXA-1        *aac(6')-Ib-cr*, *qnrB*   64/32                                              128     \>256   64    0.125   64      256     16    \>64/1216     64
  EN72                      Dog    121                                         \-                    CTX-M-15          OXA-1               *aac(6')-Ib-cr*, *qnrB*   128/64                                             256     \>256   32    0.03    32      \>256   16    \>64/1216     \>32
  EN73                      Dog    121                                         \-                    CTX-M-15          OXA-1               *aac(6')-Ib-cr*, *qnrB*   64/32                                              256     \>256   32    0.03    32      \>256   16    \>64/1216     \>32
  EN28                      Dog    136                                         \-                    CTX-M-15, CMY-2   TEM-1, OXA-1        *aac(6')-Ib-cr*, *qnrB*   64/32                                              256     \>256   256   0.06    64      256     0.5   \>64/1216     128
  EN59                      Dog    171                                         \-                    CTX-M-15          TEM-1, OXA-1        *aac(6')-Ib-cr*           64/32                                              64      \>256   32    0.06    32      256     1     \>64/1216     8
  EN63                      Dog    171                                         \-                    CTX-M-15, DHA-1   Not detected        *aac(6')-Ib-cr*, *qnrB*   64/32                                              128     256     64    0.03    64      256     128   \>64/1216     64
  EN66                      Dog    171                                         \-                    CTX-M-15          TEM-1, OXA-1        *aac(6')-Ib-cr*, *qnrB*   64/32                                              64      \>256   128   0.125   32      256     32    \>64/1216     64
  EN60                      Dog    544                                         \+                    DHA-1             Not detected        *qnrB*                    64/32                                              256     32      32    0.06    8       32      128   1/19          2
  EN3                       Dog    591                                         \-                    SHV-12            TEM-1               *qnrB*                    64/32                                              \>256   64      128   0.25    256     \>256   256   0.5/9.5       64
  EN4                       Dog    591                                         \-                    SHV-12            TEM-1               *qnrB*                    64/32                                              \>256   64      128   0.25    256     \>256   128   0.5/9.5       64
  EN5                       Dog    591                                         \-                    SHV-12            TEM-1               *qnrB*                    64/32                                              \>256   64      256   2       256     \>256   256   0.5/9.5       64
  EN7                       Cat    591                                         \-                    SHV-12, CMY-2     TEM-1               *qnrB*                    128/64                                             \>256   256     256   4       256     \>256   128   1/19          64
  EN10                      Dog    591                                         \-                    SHV-12            TEM-1               *qnrB*                    64/32                                              \>256   128     128   1       \>256   \>256   64    1/19          64
  EN12                      Dog    591                                         \-                    SHV-12            TEM-1               *qnrB*                    64/32                                              \>256   128     256   1       256     \>256   64    1/19          64
  EN14                      Cat    591                                         \-                    SHV-12            TEM-1               *qnrB*                    64/32                                              \>256   32      128   0.25    256     \>256   128   1/19          128
  EN53                      Cat    813[^a^](#t001fn001){ref-type="table-fn"}   \-                    CTX-M-3           TEM-1               *qnrS*                    64/32                                              128     256     4     0.06    256     \>256   128   \>64/1216     0.5
  *E*. *asburiae* (n = 2)                                                                                                                                                                                                                                                                 
  EN6                       Dog    \-                                          \+                    ACT-8             Not detected        Not detected              128/64                                             \>256   16      32    0.03    1       8       0.5   0.125/2.375   4
  EN20                      Dog    \-                                          \+                    ACT-3             Not detected        Not detected              64/32                                              256     64      64    0.125   2       32      2     2/38          16

^a^ New ST.

^b^ ACV, amoxicillin-clavulanic acid; CMZ, cefmetazole; CTX, cefotaxime; MPM, meropenem; TET, tetracycline; GEN, gentamicin; CHL, chloramphenicol; TMS, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin. The MIC values of ampicillin were \>256 μg/mL in all ESC-resistant *Enterobacter* spp. strains.

MLST typing of ESC-resistant *Enterobacter* spp. strains {#sec011}
--------------------------------------------------------

As shown in [Table 1](#pone.0174178.t001){ref-type="table"}, 18 ESC-resistant *E*. *cloacae* isolates investigated by MLST were assigned to eight STs: ST591 (allelic profile 3-3-110-232-19-16-17, n = 7), ST121 (10-21-9-44-45-4-32, n = 3), ST171 (49-21-19-44-45-12-32, n = 3), ST113 (4-22-68-69-37-4-24, n = 1), ST114 (53-35-20-44-45-4-6, n = 1), ST136 (74-21-74-44-45-4-6, n = 1), ST544 (10-21-9-44-45-4-33, n = 1), and ST813 (74-20-20-44-99-24-32, n = 1). [Fig 2](#pone.0174178.g002){ref-type="fig"} illustrates a population snapshot by eBURST analysis of our collection of isolates, against 827 previously-reported STs obtained from the MLST database (accessed on 30 July 2016). Of the eight STs, ST121 and ST544 were included in the same clonal complex, whereas the remaining STs were singletons or had single locus variants that were unrelated to the STs in our collection.

![Population snapshot by eBURST analysis of ESC-resistant *E*. *cloacae* strains against the entire *E*. *cloacae* MLST database.\
\*The STs identified in this study are labeled with arrows. The names of the clonal complexes are based on the ST assigned as the founder genotype. The relative size of the circles indicates the prevalence of STs and lines between STs connect single locus variants.](pone.0174178.g002){#pone.0174178.g002}

PFGE analysis of ESC-resistant *Enterobacter* spp. strains {#sec012}
----------------------------------------------------------

In PFGE analysis, ESC-resistant *E*. *cloacae* strains formed three distinct clusters ([Fig 3](#pone.0174178.g003){ref-type="fig"}). Clusters I and III consisted of three ST121-CTX-M-15 strains and seven ST591-SHV-12 strains, respectively, obtained from the same veterinary hospital. In addition, cluster II contained two ST171-CTX-M-15 strains obtained from the same hospital.

![PFGE profiles of 18 ESC-resistant *E*. *cloacae* strains from companion animals in Japan.\
\*The numbers embedded in the phylogenetic tree indicate clusters.](pone.0174178.g003){#pone.0174178.g003}

Discussion {#sec013}
==========

There have been few reports on the prevalence of antimicrobial resistance in overall populations of *Enterobacter* spp. isolates from companion animals worldwide. This study demonstrated that almost all *Enterobacter* spp. isolates in our collection exhibited resistance to β-lactams excluding AMP, ACV, and CMZ, possibly due to chromosomal AmpC β-lactamases \[[@pone.0174178.ref001],[@pone.0174178.ref002]\]. The rates of resistance to CTX and CIP in our collection (33.3% and 43.3%, respectively) were similar to those in *K*. *pneumoniae* isolates (39.3% and 41.6%, respectively) \[[@pone.0174178.ref031]\], but were much higher than those in *Proteus mirabilis* isolates (1.9% and 5.8%, respectively) \[[@pone.0174178.ref032]\] from companion animals in Japan. Compared with *Enterobacter* spp. isolates from human in Japan \[[@pone.0174178.ref033]\], the rate of CIP resistance in our collection was extremely high (4.4% vs. 43.3%). Similarly, a higher rate of CIP resistance than human isolates has been reported in *E*. *coli* \[[@pone.0174178.ref034]\] and *K*. *pneumoniae* \[[@pone.0174178.ref031]\] isolates from companion animals. These findings implied the heavy use of fluoroquinolone drugs in veterinary medicine. To evaluate inter-country diversity of the prevalence of antimicrobial-resistant *Enterobacter* spp. from companion animals, systematic surveillance would be needed in many countries.

We found higher prevalence of ESBLs in *Enterobacter* isolates (16/60, 26.7%), compared with that reported from dogs (11/314, 3.5%) and cats (11/108, 10.2%) in France \[[@pone.0174178.ref011]\] and human isolates in Japan (22/364, 6.0%) \[[@pone.0174178.ref035]\]. In addition, the carriage rate of ESBLs in our collection was slightly lower that in *K*. *pneumoniae* isolates (31/89, 34.8%) \[[@pone.0174178.ref031]\], but was much higher than that in *P*. *mirabilis* isolates (0/103, 0%) \[[@pone.0174178.ref032]\] from companion animals in Japan. These data suggest that the risk of ESBL carriage is relatively high in *Enterobacter* spp. isolates from companion animals in Japan. In this study, the major types of ESBLs were CTX-M-15 and SHV-12. Similarly, these ESBLs have been frequently detected in companion animals in France and Australia \[[@pone.0174178.ref009],[@pone.0174178.ref011]\]. As for ESBLs detected in human strains in Japan, CTX-M-3, which was an uncommon ESBL in this study (n = 1), was predominant, whereas CTX-M-15 was not detected \[[@pone.0174178.ref035]\]. These data suggest that the major types of ESBLs differ between *Enterobacter* spp. isolates from companion animals and human. Therefore, the risk of zoonotic transmission of ESBL-producing *Enterobacter* spp. is not likely to be high, although attention should be paid to *Enterobacter* spp. isolates from companion animals as reservoirs of ESBLs.

Besides ESBLs, we identified several AmpC β-lactamase genes (ACT, CMY, and DHA-type genes) in ESC-resistant strains. Notably, ACT-type enzymes are known to be representative chromosomal AmpC β-lactamases of *Enterobacter* spp. \[[@pone.0174178.ref036]\]. As for ACT-type genes, two *E*. *asburiae* strains were positive, but all of the *E*. *cloacae* strains were negative, which might imply the lack of AmpC genes or sequence variability among chromosomal AmpC genes, as previously reported \[[@pone.0174178.ref037]\]. The remaining two types of plasmid-mediated AmpC β-lactamases have rarely been identified in *Enterobacter* spp. isolated from humans \[[@pone.0174178.ref038],[@pone.0174178.ref039]\]. We also found that several non-ESBL-producing ESC-resistant strains overexpressed chromosomal AmpC β-lactamase. Our findings suggest that plasmid-mediated AmpC β-lactamases, in addition to chromosomal AmpC β-lactamases, partly contribute to ESC resistance in *Enterobacter* spp. isolates from companion animals. On the other hand, all ESC-resistant *Enterobacter* spp. strains were negative for carbapenemases. This finding indicates that carbapenemases are uncommon among *Enterobacter* spp. isolates from companion animals in Japan, as well as among other Gram-negative bacteria \[[@pone.0174178.ref031],[@pone.0174178.ref032],[@pone.0174178.ref040],[@pone.0174178.ref041]\], although they have been reported among animal isolates in other countries \[[@pone.0174178.ref012]\] and among human isolates in Japan \[[@pone.0174178.ref042]\].

All of the ESC-resistant *E*. *cloacae* strains possessed one or more PMQR genes, which is likely to contribute to the extremely high rate of CIP resistance among these strains (18/20, 90.0%). We found the high prevalence of *qnrB* and *aac(6')-Ib-cr* among ESC-resistant *Enterobacter* strains, and similar findings have been confirmed among *Enterobacter* isolates from companion animals in Australia \[[@pone.0174178.ref010]\]. Notably, most *aac(6')-Ib-cr*-positive strains also harbored OXA-1 and/or CTX-M-15 β-lactamases, which may indicate a strong association between these genes \[[@pone.0174178.ref043],[@pone.0174178.ref044]\]. In addition, we detected the *qnrS* gene, which is the most prevalent PMQR gene among ESBL-producing *Enterobacter* spp. isolates from humans in Japan \[[@pone.0174178.ref035]\] but was not previously detected among isolates from companion animals in Australia \[[@pone.0174178.ref010]\]. These findings may suggest that *qnrS* gene is locally spread among companion animals and humans in Japan.

Recently, Izdebski *et al*. \[[@pone.0174178.ref019]\] found that ST66, ST78, ST108, and ST114 strains were widely spread as high-risk international clones of ESC-resistant *E*. *cloacae*. Of these STs, ST114 was identified in our collection and was associated with CTX-M-15. This is the first report of the ST114-CTX-M-15 clone in companion animals in any country other than France \[[@pone.0174178.ref011]\]. Furthermore, we found eight STs that had not been identified in the study by Haenni *et al*. \[[@pone.0174178.ref011]\]. This implies that ESC-resistant *E*. *cloacae* isolated from different countries generally belong to different lineages. Unfortunately, the prevalence of STs has not been reported for human ESC-resistant *E*. *cloacae* isolates in Japan, and thus further studies to compare STs between animal and human isolates are needed.

Based on the PFGE analysis, we found that ESBL-producing *E*. *cloacae* clones were disseminated among different patients in the same hospital. This result strongly suggests nosocomial infections of ESBL-producing *E*. *cloacae* clones, and similar findings have previously been reported \[[@pone.0174178.ref011]\]. Surprisingly, several clones were repeatedly identified at an interval of many months, implying that ESBL-producing *E*. *cloacae* clones can survive inside or outside of hospitals for a long period \[[@pone.0174178.ref045]\]. Therefore, the dissemination of ESBL-producing *E*. *cloacae* clones among companion animals may occur not only via direct spread from animal to animal, but also via indirect transmission from potential reservoirs and sources in the environment. Our data emphasize the need for infection control in hospitals and in the community to prevent dissemination of ESBL-producing *E*. *cloacae* clones among companion animals.

Conclusion {#sec014}
==========

Our data demonstrate the high prevalence of ESBLs and PMQR genes among ESC-resistant *E*. *cloacae* strains isolated from companion animals in Japan. Epidemiological data suggest that *E*. *cloacae* clones co-harboring ESBLs and PMQR genes are disseminated via intra-hospital and inter-hospital transmission.

Supporting information {#sec015}
======================

###### The details of *Enterobacter* spp. isolates used in this study.

\*AMP, ampicillin; ACV, amoxicillin-clavulanic acid; CMZ, cefmetazole; CTX, cefotaxime; CAZ, ceftazidime, MPM, meropenem; TET, tetracycline; GEN, gentamicin; CHL, chloramphenicol; TMS, trimethoprim/sulfamethoxazole; CIP, ciprofloxacin; R, resistant.
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